Achieve Life Sciences (ACHV) Competitors $2.68 -0.02 (-0.74%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$2.68 +0.00 (+0.19%) As of 07/25/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ACHV vs. RIGL, XOMA, VNDA, VSTM, CDXS, CBIO, AGEN, IRWD, SGMO, and DOMHShould you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include Rigel Pharmaceuticals (RIGL), XOMA Royalty (XOMA), Vanda Pharmaceuticals (VNDA), Verastem (VSTM), Codexis (CDXS), Crescent Biopharma (CBIO), Agenus (AGEN), Ironwood Pharmaceuticals (IRWD), Sangamo Therapeutics (SGMO), and Dominari (DOMH). These companies are all part of the "biotechnology" industry. Achieve Life Sciences vs. Its Competitors Rigel Pharmaceuticals XOMA Royalty Vanda Pharmaceuticals Verastem Codexis Crescent Biopharma Agenus Ironwood Pharmaceuticals Sangamo Therapeutics Dominari Rigel Pharmaceuticals (NASDAQ:RIGL) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, risk, valuation, profitability, dividends, analyst recommendations, media sentiment and institutional ownership. Which has more risk & volatility, RIGL or ACHV? Rigel Pharmaceuticals has a beta of 1.26, suggesting that its share price is 26% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Do insiders & institutionals hold more shares of RIGL or ACHV? 66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 9.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 3.0% of Achieve Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has better valuation and earnings, RIGL or ACHV? Rigel Pharmaceuticals has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRigel Pharmaceuticals$203.08M1.78$17.49M$2.079.74Achieve Life SciencesN/AN/A-$39.83M-$1.34-2.00 Do analysts recommend RIGL or ACHV? Rigel Pharmaceuticals currently has a consensus target price of $36.40, suggesting a potential upside of 80.47%. Achieve Life Sciences has a consensus target price of $14.33, suggesting a potential upside of 434.83%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts clearly believe Achieve Life Sciences is more favorable than Rigel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rigel Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Achieve Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50 Is RIGL or ACHV more profitable? Rigel Pharmaceuticals has a net margin of 18.31% compared to Achieve Life Sciences' net margin of 0.00%. Achieve Life Sciences' return on equity of -176.11% beat Rigel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rigel Pharmaceuticals18.31% -655.26% 24.47% Achieve Life Sciences N/A -176.11%-103.32% Does the media refer more to RIGL or ACHV? In the previous week, Rigel Pharmaceuticals had 1 more articles in the media than Achieve Life Sciences. MarketBeat recorded 3 mentions for Rigel Pharmaceuticals and 2 mentions for Achieve Life Sciences. Rigel Pharmaceuticals' average media sentiment score of 1.63 beat Achieve Life Sciences' score of 0.93 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Achieve Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryRigel Pharmaceuticals beats Achieve Life Sciences on 10 of the 15 factors compared between the two stocks. Get Achieve Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACHV vs. The Competition Export to ExcelMetricAchieve Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$93.65M$2.49B$5.70B$9.50BDividend YieldN/A1.65%4.58%4.01%P/E Ratio-2.009.1828.4120.08Price / SalesN/A611.32432.3189.32Price / CashN/A165.2136.2258.56Price / Book4.395.168.675.88Net Income-$39.83M$30.99M$3.25B$258.89M7 Day PerformanceN/A7.73%4.25%3.71%1 Month Performance-23.65%16.27%10.51%11.72%1 Year Performance-45.58%-1.88%35.68%18.01% Achieve Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACHVAchieve Life Sciences2.8069 of 5 stars$2.68-0.7%$14.33+434.8%-45.2%$93.65MN/A-2.0020RIGLRigel Pharmaceuticals3.2002 of 5 stars$19.35+2.5%$36.40+88.1%+85.0%$345.78M$179.28M9.35160Positive NewsXOMAXOMA Royalty4.0149 of 5 stars$27.76+2.3%$69.50+150.4%-10.7%$332.20M$13.05M-24.1410News CoverageAnalyst UpgradeVNDAVanda Pharmaceuticals4.7375 of 5 stars$4.97+4.9%$16.50+232.0%-22.9%$292.90M$201.35M-6.63290Upcoming EarningsVSTMVerastem3.5303 of 5 stars$4.96+6.0%$13.38+169.7%+106.7%$272.55M$10M-1.5550CDXSCodexis3.459 of 5 stars$3.07+2.7%$11.00+258.3%-14.8%$254.35M$59.35M-3.10250News CoveragePositive NewsCBIOCrescent Biopharma3.2028 of 5 stars$12.80-1.2%$25.67+100.5%N/A$250.24M$10K-0.2850Gap UpHigh Trading VolumeAGENAgenus4.219 of 5 stars$6.83-3.3%$14.00+105.0%-0.1%$187.26M$99.52M-0.79440Positive NewsIRWDIronwood Pharmaceuticals4.3673 of 5 stars$0.74-1.9%$4.78+548.1%-88.0%$119.44M$351.41M-3.69220Positive NewsSGMOSangamo Therapeutics2.3932 of 5 stars$0.50+1.6%$4.50+800.0%-12.9%$116.59M$57.80M-1.28480Positive NewsDOMHDominari1.0874 of 5 stars$5.35+7.2%N/A+181.1%$78.35M$24.89M-1.194 Related Companies and Tools Related Companies RIGL Alternatives XOMA Alternatives VNDA Alternatives VSTM Alternatives CDXS Alternatives CBIO Alternatives AGEN Alternatives IRWD Alternatives SGMO Alternatives DOMH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACHV) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s $100 Trillion Land Rush Is OnWhat Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trill...Stansberry Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Achieve Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Achieve Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
